KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBITDA Margin (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBITDA Margin for 17 consecutive years, with 8.6% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 4617.0% to 8.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.04%, a 5475.0% increase, with the full-year FY2025 number at 14.04%, up 3193.0% from a year prior.
  • EBITDA Margin was 8.6% for Q4 2025 at Bristol Myers Squibb, down from 18.34% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 21.09% in Q4 2021 to a low of 99.16% in Q1 2024.
  • A 5-year average of 0.13% and a median of 10.46% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: surged 14181bps in 2021, then plummeted -11834bps in 2024.
  • Bristol Myers Squibb's EBITDA Margin stood at 21.09% in 2021, then plummeted by -34bps to 13.87% in 2022, then tumbled by -167bps to 9.33% in 2023, then crashed by -303bps to 37.57% in 2024, then surged by 123bps to 8.6% in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBITDA Margin are 8.6% (Q4 2025), 18.34% (Q3 2025), and 9.61% (Q2 2025).